Asparkam

General characteristics. Structure:

Active agents: tetrahydrate asparaginate magnesium (magnesian salt D, L-of aminosuccinic acid of tetrahydrate) of 175,0 mg, hydrate asparaginate ½ potassium (potassium salt D, L-aminosuccinic acid ½ of hydrate) of 175,0 mg.

Excipients: potato starch, talc, silicon dioxide colloid (aerosil), calcium stearate.

Pharmacological properties:

Pharmacokinetics. Asparaginata of potassium and magnesium are well soaked up in a GIT, are distributed on fabrics and bodies and get into cytosol where the level of potassium and magnesium significantly increases.

Pharmacodynamics. The asparkam - a source of potassium (K+) and magnesium (Mg2+), regulates metabolic processes, promotes recovery of electrolytic balance, has antiarrhytmic effect. K + participates as in carrying out impulses on nerve fibrils, and in synoptic transfer, implementation of muscular contractions, maintenance of normal cordial activity. Disturbance of exchange of K+ leads to change of excitability of nerves and muscles. Active ionic transport supports a high gradient of K+ through a plasma membrane. In small doses of K+ expands coronary arteries, in big - narrows. Renders negative hrono-and bathmotropic action, in high doses - negative other and dromotropic, and also moderate diuretic action. Mg2 + is a cofactor of 300 fermental reactions. An irreplaceable element in the processes providing receipt and an expenditure of energy. Participates in balance of electrolytes, transport of ions, permeability of membranes, neuromuscular excitability. Enters into structure (pentozofosfatny) DNA, participates in RNA synthesis, the heredity device, cellular growth, in the course of cell fission. Limits and prevents excessive release of a catecholamine at a stress, the lipolysis and release of free fatty acids are possible. Promotes penetration of K+ into cells. Asparaginate promotes penetration of K+ and Mg2 + in intracellular space, stimulates intercellular synthesis of phosphates.

Indications to use:

- the arrhythmias caused by deficit of potassium and magnesium in an organism, intoxication cardiac glycosides;

- ventricular premature ventricular contraction, atrial fibrillation paroxysms;

- circulatory unefficiency;

- coronary heart disease;

- a hypopotassemia, including correction of a hypopotassemia at use of loopback diuretics, purgatives, glucocorticosteroids.

Route of administration and doses:

Appoint inside, after food. The initial dose for adults usually makes 1–2 tablets 3 times a day within 2–3 weeks, then the dose is reduced to supporting - 1 tablet 3 times a day. A preventive dose – 1 tablet 3 times a day within 3–4 weeks. If necessary the course of treatment is repeated.

There is no experience of use for children. Doses and duration of treatment are defined individually by the doctor.

Features of use:

At prolonged use it is recommended to control the level of potassium and magnesium in blood, ECG indicators. Considering that potassium drugs at intake can irritate a mucous membrane of digestive tract, it is not recommended to accept drug on an empty stomach. At patients with insufficiency of adrenal glands the risk of development of a hyperpotassemia increases.

Data on safety and efficiency of use of drug for children are absent.

During pregnancy and feeding a breast drug is appointed in case the advantage of use exceeds potential risk for the fruit/child and under observation of the doctor.

Data on influence of drug on ability to control of vehicles and on performance of potentially dangerous types of activity are absent, but considering side effects of medicine it is necessary to be careful.

Side effects:

Seldom:

- nausea, vomiting, diarrhea, abdominal pain;

- face reddening;

- thirst.

Very seldom:

- dryness in a mouth, an ulceration of a mucous membrane of digestive tract , bleeding from bodies of a GIT, a meteorism;

- AV blockade, bradycardia;

- paresthesias;

- dizziness;

- lowering of arterial pressure;

- hyporeflexia;

- neuromuscular blockade;

- respiratory depression;

- spasms;

- hyperpotassemia, gipermagniyemiya;

- skin itch;

- perspiration.

Are possible:

- unpleasant feelings or burning sensation in epigastric area (at patients of patients with cholecystitis and anacid gastritis).

Interaction with other medicines:

Reduces sensitivity to cardiac glycosides. Strengthens effect of the medicines stimulating trophic processes in a myocardium. At simultaneous use of an asparkam with kaliysberegayushchy diuretics and/or with inhibitors of an angiotensin-converting enzyme, heparin, nonsteroid antiinflammatory medicines the risk of development of a hyperpotassemia and gipermagniyemiya increases. Inhibits absorption of tetracycline, iron salts. Reduces efficiency of streptomycin. Drugs of calcium reduce efficiency of an asparkam.

Contraindications:

- the increased individual sensitivity to drug components;

- hyperpotassemia;

- gipermagniyemiya;

- myasthenia;

- acute and chronic renal failure;

- atrioventricular block of the II-III degree;

- the expressed arterial hypotension;

- hemolysis;

- Addison's disease;

- anury;

- children's age up to 18 years.

Overdose:

At use in the doses considerably exceeding averages therapeutic aggravation of symptoms of a hyperpotassemia and gipermagniyemiya is possible. These phenomena usually disappear at reduction of a dose of drug or its cancellation.

Treatment. Introduction intravenously Calcii chloridum, if necessary – a hemodialysis, peritoneal dialysis.

Storage conditions:

To store in the dry, protected from light place at a temperature not above 30 °C.

To store in the place, unavailable to children!

Issue conditions:

Without recipe

Packaging:

On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil.

Blister strip packagings place in boxes from a cardboard together with the instruction on a medical use in the state and Russian languages.